This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Iomeprol is an iodine-based X-ray contrast agent.
- Generic Name
- Iomeprol
- DrugBank Accession Number
- DB11705
- Background
Iomeprol has been investigated for the diagnostic of Coronary Artery Disease.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Iomeprol (DB11705)
- Weight
- Average: 777.089
Monoisotopic: 776.8541 - Chemical Formula
- C17H22I3N3O8
- Synonyms
- Iomeprol
- Iomeprolum
- External IDs
- E7337
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Iomeron Injection, solution 510 mg/1mL Intravascular BIPSO GmbH 2022-07-01 Not applicable US 
Iomeron Injection, solution 714 mg/1mL Intravascular BIPSO GmbH 2022-07-01 Not applicable US Iomeron Injection, solution 714 mg/1mL Intravascular Bracco Diagnostics Inc 2022-07-01 Not applicable US Iomeron Injection, solution 612 mg/1mL Intravascular Bracco Diagnostics Inc 2022-07-01 Not applicable US Iomeron Injection, solution 612 mg/1mL Intravascular BIPSO GmbH 2022-07-01 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Iomeron Iomeprol (510 mg/1mL) Injection, solution Intravascular BIPSO GmbH 2022-07-01 Not applicable US Iomeron Iomeprol (714 mg/1mL) Injection, solution Intravascular BIPSO GmbH 2022-07-01 Not applicable US Iomeron Iomeprol (714 mg/1mL) Injection, solution Intravascular Bracco Diagnostics Inc 2022-07-01 Not applicable US Iomeron Iomeprol (612 mg/1mL) Injection, solution Intravascular Bracco Diagnostics Inc 2022-07-01 Not applicable US Iomeron Iomeprol (612 mg/1mL) Injection, solution Intravascular BIPSO GmbH 2022-07-01 Not applicable US
Categories
- ATC Codes
- V08AB10 — Iomeprol
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Acylaminobenzoic acid and derivatives
- Alternative Parents
- 2-halobenzoic acids and derivatives / 4-halobenzoic acids and derivatives / Anilides / Benzamides / Benzoyl derivatives / Iodobenzenes / Aryl iodides / Vinylogous halides / Tertiary carboxylic acid amides / Secondary carboxylic acid amides show 8 more
- Substituents
- 2-halobenzoic acid or derivatives / 4-halobenzoic acid or derivatives / Acylaminobenzoic acid or derivatives / Alcohol / Anilide / Aromatic homomonocyclic compound / Aryl halide / Aryl iodide / Benzamide / Benzoyl show 20 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- organoiodine compound, benzenedicarboxamide (CHEBI:31710)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 17E17JBP8L
- CAS number
- 78649-41-9
- InChI Key
- NJKDOADNQSYQEV-UHFFFAOYSA-N
- InChI
- InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31)
- IUPAC Name
- N1,N3-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-methylacetamido)-2,4,6-triiodobenzene-1,3-dicarboxamide
- SMILES
- CN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I
References
- General References
- EMC Summary of Product Characteristics: Iomeron (iomeprol) solution for injection [Link]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Diagnostic Coronary Artery Disease (CAD) 1 4 Completed Prevention Angioplasty, Transluminal, Percutaneous Coronary / Coronary Arteriosclerosis / Renal Insufficiency,Chronic 1 4 Completed Supportive Care Contrast Agent With Lean Body Weight 1 2, 3 Completed Diagnostic Liver Lesions 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intravascular 510 mg/1mL Injection, solution Intravascular 612 mg/1mL Injection, solution Intravascular 714 mg/1mL Injection, solution Intravascular 816 mg/1mL Injection, solution Parenteral 150 MG/ML Injection, solution Parenteral 200 MG/ML Injection, solution Parenteral 250 MG/ML Injection, solution Parenteral 300 MG/ML Injection, solution Parenteral 350 MG/ML Injection, solution Parenteral 400 MG/ML Solution Intravenous 816.5 mg Injection, solution Parenteral 30.62 g/100ml Injection, solution Parenteral 306 mg/ml Injection, solution Parenteral 40.82 g/100ml Injection, solution Parenteral 51.03 g/100ml Injection, solution Parenteral 510 mg/ml Solution Intravenous 300 mg/1ml Injection Intravascular 300 mg/ml Injection, solution Parenteral 612 mg/ml Injection, solution Parenteral Injection, solution Parenteral 61.24 g/100ml Solution Intravenous 350 mg/1ml Injection Intravascular 350 mg/ml Injection, solution Parenteral 714 mg/ml Injection, solution Parenteral 71.44 g/100ml Injection Intrathecal; Intravascular Solution Intravenous 400 mg/1ml Injection Intravascular 400 mg/ml Injection, solution Parenteral 817 mg/ml Injection, solution Parenteral 81.65 g/100ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.595 mg/mL ALOGPS logP -2.5 ALOGPS logP -1.4 Chemaxon logS -3.1 ALOGPS pKa (Strongest Acidic) 11.73 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 7 Chemaxon Polar Surface Area 179.66 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 138.29 m3·mol-1 Chemaxon Polarizability 55.44 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 216.731 predictedDeepCCS 1.0 (2019) [M+H]+ 219.089 predictedDeepCCS 1.0 (2019) [M+Na]+ 225.49132 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 20:41 / Updated at May 07, 2021 21:07